HOT HOT HOT ck you email from the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 30, 2012 at 7:47 PM

HOT HOT HOT ck you email from the company

Cellceutix Anti-Cancer Drug Kevetrin Completes Dosing Cycle, Ready for Next Cohort

BEVERLY, MA – December 3, 2012--Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that clinical trials for Kevetrin™, the Company’s flagship anti-cancer drug, are progressing smoothly. In the clinical trials, being conducted at Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center, the cohort which began treatment with Kevetrin early in November has completed the initial cycle.

To date, the group of subjects has been reported to be within normal parameters of the clinical protocol. A total of 84 blood samples from the patients have just been sent to the laboratory for pharmacokinetics analysis.

As per the clinical protocol, the Safety Committee will now meet to approve continuation of dose administration for the benefit of that group of patients and to approve increasing the dose for the next group of patients, which the Company expects to begin in mid-December.

“The clinical trials are progressing extremely well and right on schedule,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “As we await the lab reports, it’s very encouraging that we have not seen any of the toxic side effects that are commonly associated with chemotherapy at this point. Many new drugs demonstrate toxicity immediately, so I interpret the information on Kevetrin™ with a great deal of optimism. We are excited for the upcoming weeks when the next cohort, in which dosing levels will be doubled, may provide us even greater insight on what we believe is the most exciting oncologic drug in development today.”

Regarding Prurisol™, the Company’s drug in development as a new therapy for psoriasis, Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) has advised the Company that scale-up manufacturing is underway. During the pilot developmental studies, Dr. Reddy’s was able to improve the yield and purity and reduced the synthetic steps required. This will save Cellceutix valuable time and money in the manufacturing of Prurisol for the planned Phase 2 / 3 clinical trials.”

About Kevetrin™

As a completely new class of chemistry in medicine, Kevetrin™ has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.

In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.
The clinical trial titled, "A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is available at: http://clinicaltrials.gov/ct2/show/NCT0166400...amp;rank=1

About Cellceutix

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at www.cellceutix.com .

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission.

Cellceutix Corp.
Leo Ehrlich
(978) 236-8717
info@cellceutix.com

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hydden Welcomes Cybersecurity Veteran Charles Tango as CSO

Unpacking Charles Tango's Move to Hydden Nobody expects cybersecurity to be a stroll in the park, and it looks like Hydden just upped its game by bringing in Charles Tango, a heavyweight turned strategy guru. You might not know him, but this guy's got a track record that shouldn’t be ignored—like a grizzled old prizefighter just itching for a new opponent. A Veteran...

Kaolin Market Surges to $8.89B by 2031: Key Trends

Riding the Kaolin Wave: Industrial Market Expansion You can't miss the sound of kaolin clinking in as it rides the tide of industrial demand. Reports from MarketsandMarkets™ have kaolin's party rocking all the way to a hefty $8.89 billion by 2031, up from $6.19 billion in 2026. With a sensible 7.5% compound annual growth rate (CAGR), this clay’s is aiming for the...

Laser Weapon Market to Double: Military Demand Surges

Pew Pew: Lasers Are the Future of Defense Forget lightsabers, we've got something even flashier—a market that's going to double in worth by 2035. High-energy laser weapons are coming in hot, growing from USD 2.17 billion in 2026 to an estimated USD 4.54 billion by the end of 2035. That's no small potatoes! What's Driving This Beam Dream? The military is all about upping...

Coretek Joins CRN's Elite AI Innovators of 2026

Coretek's Leap to AI Innovator Status Here we are, folks. Another announcement hits the wires that showcases a company's ascent amid the swelling AI tide. Coretek, hailing from Farmington Hills, managed to snag a spot on CRN's inaugural 2026 AI Innovators list. No small potatoes, if you ask me, considering the competition on this playing field. Why the fuss? It's about...

Segway Powersports Charges Ahead with MY27, iFUN 2.0

Rolling Out Power and Tech at EICMA 2026 A real gearhead's delight rolled out at EICMA 2026, with Segway Powersports lighting up the stage showcasing their 2027 upgrades. If you're betting on somewhere as time-honored for two- and four-wheeling wonders as EICMA, you know stakes get real high. Segway's making noise with their MY27 lineup and a next-gen iFUN 2.0, aiming to...

Askey & Icom Team Up: Trading Airwaves for Partnerships

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...

NOVOS Trial Boosts Vascular Health: A New Horizon

Watch Out, Aging: NOVOS Is Making Waves Aging ain't what it used to be, and longevity's becoming the golden chalice of the wellness world. Surrounded by a sea of questionably effective supplements, NOVOS, a biotech firm focused on prolonging the healthy years of life, steps up with some hard evidence. Their STAMINA trial, published in the European Heart Journal Open,...

Minghui and ASKA Seal Major Licensing Deal for MHB018A

Breaking New Ground in Thyroid Eye Disease Treatment If there's one thing that keeps the biopharma world on its toes, it's the relentless pursuit of groundbreaking treatments. And folks, let me tell you, the latest tie-up between Minghui Pharmaceutical and ASKA Pharmaceutical has struck a chord. This union with MHB018A at its core might be one of those watershed moments...

A2Gold Tackles Tough Terrain at Eastside Project

Drilling Challenges and Initial Observations Folks, it's a roller coaster out there—A2Gold just wrapped up a gritty round of drilling at their Eastside Gold-Silver Project near Tonopah, Nevada. They've punched through five reverse circulation (RC) holes, totaling 1,936 meters, all while battling tough conditions. You could say they've truly earned their stripes in the...

HashKey and AMBR Unite to Push AI Frontiers in Finance

Shaping the Future with AI Integration In the whirlwind of innovation, there's always the ones braving the frontier, pushing the very boundaries of what we deem possible. Today, it's HashKey Capital and AMBR joining forces, marching into uncharted financial territories. This partnership is more than just a signature on a piece of paper; it's a declaration—a commitment...